|Description||Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.|
|Purification||Antigen affinity column|
|Concentration||0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. (It may be customized for bulk orders.)|
|Reconstitution||Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.|
|Specificity||The product is specific for Nivolumab. This antibody serves as an excellent positive control for Nivolumab immunogenicity (ADA) assays.|
|Storage||The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.|
|Note||GenScript can customize this product per customer's request including product size, buffer components, etc.|
|Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.02-1 µg/ml
Other applications: user-optimize
For more documents, please visit "Technical Support".